2019 Speakers

Jan De Backer, MSc, PhD, MBA

Jan DeBacker

Dr. De Backer graduated from Delft University of Technology, The Netherlands as aerospace engineer. He attained an MSc degree in aerodynamics and specialized in applied biomedical computational fluid dynamics leading to a PhD from the University of Antwerp, Belgium. He is an alumnus of the MBA programs at London Business School, London and Columbia Business…

Read More

Simon Walsh, MD

Simon Walsh

Simon Walsh is a Thoracic Radiologist and National Institute of Health Research Clinician Scientist working at the National Heart and Lung Institute, Imperial College, London. He is also a Machine Learning scientist. His research interests include diagnosis and outcome prediction in pulmonary fibrosis and the application of artificial intelligence to image analysis and computer vision.…

Read More

Mark Gelfand

Mark Gelfand

Mr. Gelfand has more than 25 years of experience innovating medical devices in academic, startup and corporate environments. With Dr. Levin, he co-founded 10 venture-funded startups and served as the CTO to those ventures. Prior to becoming an entrepreneur, Mr. Gelfand worked at Nellcor Puritan Bennett, the world’s leading respiratory device company, where he was…

Read More

Jonathan Phillips

Jonathan Phillips

Dr. Jonathan Phillips joined Amgen in 2013 as a Principal Scientist and since March 2018 has served as the Global Discovery Research Lead for respiratory drug discovery where he is responsible for target identification and discovery strategies that ensure candidate molecules progress through early clinical development. Prior to joining Amgen, he worked in several respiratory…

Read More

Cayce Denton

Cayce Denton is a member of the healthcare investment team at Temasek, where she covers US therapeutics investing for both private and public companies. Private healthcare investments she has led at Temasek include Aerogen, Locana and Viela Bio. Previously, Cayce was in biotech venture capital at TPG Biotech, in operating roles at Genentech and Novartis,…

Read More

Jason Pesterfield

Jason Pesterfield

Jason has been in the Med-Tech space for 25 years with the majority of his career spent leading efforts around the development and commercialization of cutting edge technologies such as surgical power tools, navigation and robotics. At Veran, Jason and his team’s mission is to enable thoracic and interventional specialists to diagnose soft tissue cancers…

Read More

C. Matthew Kinsey, MD, MPH

C. Matthew Kinsey

Dr. Kinsey directs the Interventional Pulmonary Program at the University of Vermont Medical Center. This program focuses on advanced diagnostic and therapeutic procedures to address thoracic diseases, and includes endobronchial valve placement for advanced emphysema, intraoperative cone beam navigational bronchoscopy, holmium and Nd:YAG laser therapy, airway stenting, and direct tumoral therapies (Endobronchial Ultrasound-Guided Transbronchial Needle…

Read More

Jonathan Waldstreicher, MD, MBA

Jonathan Waldstreicher

Jonathan Waldstreicher, Principal, joined Apple Tree Partners in 2013 to invest in medical devices. After incubating an interventional pulmonary technology for two years, Jon founded Gala Therapeutics in Silicon Valley and assumed the CEO role to further its development. Prior to joining ATP, Jon was a Director, Global Surgery R&D, at Johnson & Johnson where…

Read More

Charles Hamilton

Charles

Charles Hamilton is a director and member of the Piper Jaffray healthcare investment banking team, focusing on medical technology companies. Hamilton has 14 years of healthcare investment banking and capital markets experience. He has advised public and private clients through a broad range of investment banking services, including sell-side and buy-side mergers and acquisitions as…

Read More

Benjamin Kramer, MD

Ben Kramer

Benjamin Kramer, MD is the Vice President, Medical Affairs for Immunology and Ophthalmology at Genentech. He has worked for nearly 20 years in the pharmaceutical industry, with significant leadership experience in both global clinical development and global medical affairs in respiratory, urology and immunology. Ben came to Genentech in 2012 from Novartis, where he acted…

Read More